Anti-CA19.9 376/G8
Anti-CA19.9 376/G8 - Image 2
Anti-CA19.9 376/G8 - Image 3
  1. Anti-CA19.9 376/G8
  2. Anti-CA19.9 376/G8 - Image 2
  3. Anti-CA19.9 376/G8 - Image 3

Anti-CA19.9 376/G8

ID: AK1052 Category:

Anti-CA19.9 376/G8 is a mouse monoclonal antibody against Carbohydrate Antigen 19-9 (CA19-9), also known as sialyl-Lewis-A antigen.

The antibody is produced exclusively under serum-free conditions from hybridoma and purified through one-step purification with Protein-G affinity chromatography.

In stock

Delivery time: 2-5 days

From: 610,00 € Excl. VAT and delivery costs

Please contact us for larger quantities.

Anti-CA19.9 376/G8 is a mouse monoclonal antibody against Carbohydrate Antigen 19-9
(CA19-9), also known as sialyl-Lewis-A antigen. Structurally, CA19-9 is a tetrasaccharide
attached to O-glycans of transmembrane proteins with glycosylated extracellular
oligosaccharide chains [1].

CA19-9 is an important serum marker for diagnosis, treatment decisions and prognosis of
pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers [2]. Still, there are usage
limitations. Amongst others, benign conditions, like pancreatitis, cirrhosis, lever fibrosis or
diabetes mellitus, resulting in increased CA19-9 levels can lead to false positive results [1].
Furthermore, the inability of some people with a Lewis (a- b-) blood genotype to produce CA19-9
can lead to false negative results [3].

The antibody is produced exclusively under serum-free conditions from hybridoma and purified
through one-step purification with Protein-G affinity chromatography.

 

Product-ID: AK1052
Immunogen: Native CA19-9 derived from a human cell line
Host: Mouse
Clonality: Monoclonal
Isotype: IgG1
Formulation: Clear Liquid, PBS, pH 7.4, 0.2 μm sterile filtered
Concentration: ≥ 0.5 mg/mL
Purity: ≥ 90% (CGE, reducing conditions); Two bands occur on the order of magnitude of the heavy chain
≤ 10 % aggregates (analytical SEC)
Storage: 2 - 8°C

 

The product is for research use or for further manufacturing only.

Additional information

Literature

[1] T. Lee, T. Z. J. Teng, and V. G. Shelat, “Carbohydrate antigen 19-9 — tumor marker: Past, present, and future,”
World J. Gastrointest. Surg., vol. 12, no. 12, pp. 468–490, 2020, doi: 10.4240/wjgs.v12.i12.468.
[2] G. L. Perkins, E. D. Slater, G. K. Sanders, and J. G. Prichard, “Serum tumor markers,” Am. Fam. Physician, vol. 68,
no. 6, pp. 1075–1082, 2003, doi: 10.29309/tpmj/2006.13.01.5043.
[3] M. Parra-Robert, Víc. M. Santos, S. M. Canis, X. F. Pla, J. M. A. Fradera, and R. M. Porto, “Relationship between
CA 19.9 and the lewis phenotype: Options to improve diagnostic efficiency,” Anticancer Res., vol. 38, no. 10, pp.
5883–5888, 2018, doi: 10.21873/anticanres.12931.
Document

Product Information Sheet – AK1052
Notice

The product is for research use or for further manufacturing only.

Reviews

There are no reviews yet.

Be the first to review “Anti-CA19.9 376/G8”